期刊文献+

醋酸甲地孕酮分散片的制备与质量评价 被引量:1

Preparation and Quality Evaluation of Megestrol Acetate Dispersible Tablets
下载PDF
导出
摘要 目的筛选醋酸甲地孕酮分散片的最优处方及工艺并评价制剂质量。方法用正交实验设计方法对处方工艺进行筛选与优化,制成醋酸甲地孕酮分散片;采用紫外-可见分光光度法测定其溶出度,高效液相色谱法测定主药及有关物质的含量。结果优选出的处方为:醋酸甲地孕酮53%、乳糖20%、羟丙甲纤维素1%、微晶纤维素8%、羧甲基淀粉钠10%,微粉硅胶3%、硬脂酸镁1%。实验表明该分散片崩解时限<90 s,分散均匀性较好,15 min溶出度>85%。结论所优选的处方合理,制备工艺简便,符合2010年版《中华人民共和国药典》有关分散片的质量要求。 ObjeCtive T0 Optimize the preparation technology and the formula of megestrol acetate dispersible tablets and evaluate the quality, Methods Orthogonal L9 ( 3^4 ) test was designed to optimize the prescription. UV spectrophotometry was used to detect dissolution of megestrol acetate dispersible tablets and HPLC method was established to determine the content of meges|rol acetate and the related substances. Results 20% of lactose , 1% of hydroxypropyl methyl Cellulose, 8% 3% of colloidal silicon tli0xide, 1% ~ inagnesium stearate The optimized prescription assembly was 53% of megestrol acetate, of microcrystalline cellulose, 10% of sodium carboxy methyl starch, The test showed that disintegration time was less than 90 seconds, dispersible homogeneity Was good,and dissolution rate at 15 min was more than 85%. Conclusion The optimal prescription is feasible, the preparatiori technology was simple and convenient. The dispersible tablets conform to the quality standard in the ~Chinese Pharmacopoeia 2010 edition of general preparations.
出处 《医药导报》 CAS 北大核心 2013年第10期1340-1343,共4页 Herald of Medicine
基金 2011年浙江省新苗人才计划项目(2011R34007) 浙江医学高等专科学校科研项目(2010XX01)
关键词 甲地孕酮 醋酸 分散片 制备 质量评价 Megestrol, acetate Dispersible tablet Preparation Quality evaluation
  • 相关文献

参考文献5

二级参考文献30

共引文献16

同被引文献17

  • 1杜敏,刘延超,王萍,曾宝珠.伊班膦酸钠并醋酸甲地孕酮对癌症骨转移癌患者疼痛及生活质量的影响[J].临床荟萃,2006,21(1):39-40. 被引量:3
  • 2谷铣之,殷蔚伯,余子豪,等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008:573.
  • 3Jemal A, Bray F, Center M M, et al.Global cancer statistics[J]. CACancerJClin, 2011, 61 (4): 69, 90.
  • 4Ferlay J, Shin I-I R, Bray F D, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (4) : 2893-2917.
  • 5Jemal A, Siegel R, Xu J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60 ( 7 ) : 277-300.
  • 6Shao Q, Quyang J, Fan Y, et al.Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at Muhi institutional collaboration[J].Cancer Lett, 2012, 315 ( 2 ) : 170-177.
  • 7Peyromaure E M, Man K, Sun Y, et al.A comparative study of prostate cancer detection and management in China and in France[J].Can J Urol, 2009, 16 ( 1 ) : 4472-4477.
  • 8Bubendorf L, Schopfer A, Wagner U, et akMetastatic patterns of prostate cancer: an autopsy study of 1589 patients[J].Hum Pathol, 2000, 31 (4) : 578-583.
  • 9Cooper C R, Chay C H, Gendernalik J D, et al.Stronmal factors involved in prostate carcinoma metastasis to bone[J]. Cancer, 2003, 97 (Suppl) : 739-747.
  • 10Melstrom L G, Melstrom K A Jr, Ding X Z, et al.Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia[J].Histol Histopathol, 2009, 22 ( 7 ) : 805-814.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部